Johnson & Johnson Rally Has Further Upside, Analysts Say
Both Jim Cramer and UBS see more room for J&J shares to climb as the stock pushes toward record highs.
Johnson & Johnson shares have been on a notable upward trajectory, and market watchers are increasingly confident the move is not yet exhausted. Both CNBC's Jim Cramer and analysts at UBS have aligned on the view that the pharmaceutical and medical-device giant still has meaningful upside ahead, even as it flirts with record price levels.
The convergence of a prominent television personality and a major institutional research desk on the same bullish thesis is itself a signal worth noting. When retail-facing commentary and Wall Street analysis point in the same direction, it often reflects a broader consensus forming around a stock's fundamental story — in J&J's case, a narrative built on durable revenue streams, pipeline strength, and the company's evolution following its consumer health spinoff.
Read more US-Iran Fighting Rattles Markets as Oil Tops $90 on Sept. 1 →
J&J's strategic repositioning has been a defining chapter for the company in recent years. Having separated its consumer brands into the standalone Kenvue entity, J&J has sharpened its focus on higher-margin pharmaceutical and MedTech businesses. That structural shift has given institutional investors a cleaner, more growth-oriented story to underwrite — and analysts appear to believe the market has not yet fully priced in the benefits of that transformation.
For investors weighing whether to add exposure at elevated price levels, the key question is whether the drivers underpinning the rally are durable or speculative. The UBS and Cramer alignment suggests the former — that earnings visibility, pipeline catalysts, and segment margins justify continued appreciation rather than a short-term momentum trade. That said, any stock approaching record highs carries inherent risk if sentiment shifts or macro headwinds intensify.
Continue reading at US Top News and Analysis.
